These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 28626771

  • 1. Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.
    Shimoda M, Miyoshi-Takai M, Irie S, Tanabe A, Obata A, Okauchi S, Hirukawa H, Kimura T, Kohara K, Kamei S, Mune T, Kaku K, Kaneto H.
    J Diabetes Res; 2017; 2017():5856475. PubMed ID: 28626771
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R, Uchida T, Kimura K, Yamada Y.
    Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
    [Abstract] [Full Text] [Related]

  • 3. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A, Lee S, Scowcroft A, Bingham-Gardiner P, Spencer W, Bolodeoku J, Hassan SW.
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
    Park SH, Nam JY, Han E, Lee YH, Lee BW, Kim BS, Cha BS, Kim CS, Kang ES.
    Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
    [Abstract] [Full Text] [Related]

  • 9. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.
    Ned Tijdschr Geneeskd; 2010 Aug; 154():A886. PubMed ID: 20298625
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Aug; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 11. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Chen YW, Wang JS, Sheu WH, Lin SY, Lee IT, Song YM, Fu CP, Lee CL.
    PLoS One; 2017 Aug; 12(2):e0171753. PubMed ID: 28182722
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V, Del Prato S, Araga M, Kothny W.
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [Abstract] [Full Text] [Related]

  • 14. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S.
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 17. Effect of vildagliptin on hepatic steatosis.
    Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Al-Mrabeh A, Schweizer A, Foley JE, Taylor R.
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1578-85. PubMed ID: 25664602
    [Abstract] [Full Text] [Related]

  • 18. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [Abstract] [Full Text] [Related]

  • 19. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
    Nishida Y, Takahashi Y, Tezuka K, Akimoto H, Nakayama T, Asai S.
    BMC Pharmacol Toxicol; 2020 Apr 21; 21(1):28. PubMed ID: 32317005
    [Abstract] [Full Text] [Related]

  • 20. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
    Shimodaira M, Niwa T, Nakajima K, Kobayashi M.
    Endocr Metab Immune Disord Drug Targets; 2015 Apr 21; 15(3):223-8. PubMed ID: 25809193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.